Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.42 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18820441 | 0.79 | CHRM4 (0.32) | — | |
| SCHEMBL15612889 | 0.78 | DYRK1A (0.42) | KDM4EDYRK1AALDH1A1KMT2AMEN1 | |
| SCHEMBL30739243 | 0.76 | MTAP (0.31) | — | |
| SCHEMBL21985981 | 0.76 | — | — | |
| SCHEMBL10120463 | 0.76 | MTAP (0.47) | LMNA | |
| SCHEMBL2432745 | 0.76 | DYRK1A (0.41) | KDM4EDYRK1AALDH1A1KMT2AMEN1 | |
| SCHEMBL29971950 | 0.76 | DYRK1A (0.41) | KDM4EDYRK1AALDH1A1KMT2AMEN1 | |
| SCHEMBL18558186 | 0.76 | CHEK1 (0.52) | KDM4EDYRK1AALDH1A1KMT2AMEN1 | |
| SCHEMBL25636036 | 0.73 | FFAR2 (0.37) | — | |
| SCHEMBL15612877 | 0.73 | PDPK1 (0.49) | KDM4EALDH1A1KMT2AMEN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11795169-B2 | MAP4K4 inhibitors | IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) | 2023-10-24 | — | — | US | disclosed |
| WO-2020115481-A1 | MAP4K4 INHIBITORS | IMPERIAL COLLEGE OF SCIENCE, TECHNOLOGY AND MEDICINE (GB) | 2020-06-11 | — | — | WO | disclosed |
| WO-2019073253-A1 | MAP4K4 INHIBITORS | IMPERIAL INNOVATIONS LIMITED (GB) | 2019-04-18 | — | — | WO | disclosed |
| US-20170128454-A1 | COMPOSITIONS AND METHODS FOR INHIBITING VIRAL POLYMERASE | BIOCRYST PHARMACEUTICALS, INC. | 2017-05-11 | — | — | US | disclosed |
| US-9580428-B2 | Compositions and methods for inhibiting viral polymerase | BIOCRYST PHARMACEUTICALS, INC. (US) | 2017-02-28 | — | — | US | disclosed |
| US-20150191472-A1 | COMPOSITIONS AND METHODS FOR INHIBITING VIRAL POLYMERASE | BIOCRYST PHARMACEUTICALS, INC. | 2015-07-09 | — | — | US | disclosed |
| WO-2013158746-A1 | COMPOSITIONS AND METHODS FOR INHIBITING VIRAL POLYMERASE | BIOCRYST PHARMACEUTICALS, INC. (US) | 2013-10-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170128454-A1 | COMPOSITIONS AND METHODS FOR INHIBITING VIRAL POLYMERASE | POLRMT, POLR1E, POLR1A | KDM4E 3466/4885DYRK1A 4874/4885ALDH1A1 1800/4885 |
| US-20150191472-A1 | COMPOSITIONS AND METHODS FOR INHIBITING VIRAL POLYMERASE | POLRMT, POLR1E, POLR1A | KDM4E 3466/4885DYRK1A 4874/4885ALDH1A1 1800/4885 |
| US-11795169-B2 | MAP4K4 inhibitors | MAP4K4, MAP4K2, MAP4K5 | KDM4E 742/4885DYRK1A 861/4885ALDH1A1 1426/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.